Are Eye Injections Safe During Pregnancy or While Breastfeeding?
Eye Injections in Pregnancy and Breastfeeding: What to Know
There is no simple yes or no, and honest guidance says so. Anti-VEGF eye injections have not been proven safe or unsafe in pregnancy, because the evidence is limited to a small number of reported cases. Expert guidance is to avoid these injections in pregnancy when it is reasonably possible, especially early on, and to decide each case together with your eye doctor and your pregnancy care team2. Sometimes the safest choice is to wait or use another treatment; sometimes it is to treat, to protect sight. This page helps you have that conversation, not replace it.
One thing is not a judgment call. Being pregnant or breastfeeding is not a reason to delay care for sudden vision changes, and some retinal conditions can cause permanent damage if they are not treated in time1. New floaters or flashes, a dark curtain or shadow, sudden blurring, or loss of vision all need prompt evaluation. Getting checked does not commit you to any particular treatment; it simply makes sure a sight-threatening problem is not missed.
The most useful thing you can do is make sure everyone knows. Tell your eye doctor if you are pregnant, might be, are trying to conceive, or are breastfeeding, because in the largest review about 4 in 10 patients did not know they were pregnant at the time of injection1. Ask your retina specialist and obstetrician to talk to each other. Together they can weigh your eye condition against the pregnancy and help you choose.
What Anti-VEGF Eye Injections Are and Why They Are Used
Anti-VEGF injections are medicines placed into the eye to reduce abnormal blood-vessel growth and leakage in the retina. The main ones are bevacizumab (Avastin), ranibizumab (Lucentis), aflibercept (Eylea), brolucizumab (Beovu), and faricimab (Vabysmo)7. They all block a signal called VEGF that drives leaky, fragile vessels. They are given as a quick injection in the office, often repeated over months.
Reproductive-age patients can need these for several conditions. They are used for diabetic retinopathy and diabetic macular edema, swelling after a retinal vein blockage, abnormal new vessels under the retina, and conditions like Coats disease1. Some of these can worsen during pregnancy, especially diabetic eye disease, which is part of why the question comes up. Your specific condition shapes how urgent treatment is.
The Concern in Pregnancy
The reason for caution is biological, not just legal. VEGF, the very signal these drugs block, is essential for a healthy placenta and for the baby's developing blood vessels, so blocking it is a theoretical concern during pregnancy1. This is why the drugs' own labels state that, based on how they work, they may pose a risk to a developing baby. It is a reasoned concern about mechanism, which is different from proof of harm.
An eye injection is local, but not entirely sealed off from the body. A small amount of the drug escapes the eye into the bloodstream and can briefly lower circulating VEGF, and this systemic footprint differs by drug, with ranibizumab having the least3. The amounts are far lower than the same drugs given for cancer through a vein. Still, because any drop in VEGF is theoretically relevant to a pregnancy, the small systemic exposure is part of the discussion.
Here honesty matters most, in both directions. In the largest review, of 42 pregnancies exposed to these injections, most, about 8 in 10 (34 of 42), ended in a live birth, while about 5 miscarried and about 3 were stillbirths, and the losses mostly occurred in women who already had significant risk factors1. A separate analysis of a drug-safety database flagged a possible signal of pregnancy loss, but its authors stressed it cannot prove cause and is only a starting point for study4. Because miscarriage is common anyway, these numbers can neither prove nor rule out that the drug caused harm.
How Doctors Approach Treatment in Pregnancy
The general approach is caution weighted toward early pregnancy. Experts generally advise avoiding planned anti-VEGF injections in pregnancy where feasible, and avoiding the first trimester in particular, because the developing organs are most vulnerable then2. That does not mean treatment is forbidden at any stage. It means that when there is room to wait or choose another option, doing so is usually preferred, and the earliest weeks call for the most caution.
Anti-VEGF is not the only tool. Depending on the condition, other options may fit better during pregnancy. These can include laser treatment such as focal or panretinal photocoagulation for diabetic disease, a steroid option for some swelling, or careful observation, since some pregnancy-related swelling improves after delivery2. Which alternatives make sense depends entirely on your specific diagnosis, so this is something to map out with your retina specialist.
Sometimes the injection is the safer path. When an eye condition is actively threatening sight and could cause permanent, irreversible damage, treating may protect vision that waiting would cost, and untreated abnormal vessels can leave lasting structural damage1. In that situation the balance can tip toward treatment even in pregnancy. Neither treating nor waiting is automatically safer; it depends on the condition, the trimester, and how much sight is at stake.
Breastfeeding and Eye Injections
Breastfeeding is generally viewed more reassuringly than pregnancy, though data are still limited. These drugs are large protein molecules that pass into breast milk only in tiny amounts and are largely broken down in a baby's stomach, so drug-in-milk references generally consider breastfeeding compatible and often prefer ranibizumab because of its low systemic exposure6. For bevacizumab, measured milk levels after an eye injection have been very low or undetectable5. A pump-and-discard interval is sometimes suggested as extra caution but is not clearly required by the evidence.
This is an area where trustworthy sources genuinely differ, and you deserve to know that. Specialized breastfeeding databases treat these injections as compatible with nursing, while some drug labels, such as aflibercept, say breastfeeding is not recommended during treatment8. The disagreement reflects how little direct data exist, not a hidden danger. Because the guidance is not settled, the right move is to discuss your specific drug and situation with your eye doctor and pediatrician rather than rely on one source.
Medicines, Approval, and Contraception
The approval picture affects one drug in particular. Bevacizumab (Avastin) is FDA-approved as a cancer treatment, not for the eye, so its widespread use as an eye injection is off-label, supported by experience and studies but not an FDA-approved eye use7. Ranibizumab, aflibercept, brolucizumab, and faricimab are instead FDA-approved for retinal conditions9. None of these drugs is approved specifically for use during pregnancy; labels advise using them in pregnancy only if the benefit justifies the potential risk to the baby8.
If you could become pregnant, the labels ask you to plan ahead. Labels for some of these drugs advise using effective contraception before starting, during treatment, and for a few months after the last injection8. The exact interval varies by drug, so ask which applies to yours. This guidance exists because of the theoretical risk to a pregnancy, not because a problem has been proven, and it is worth discussing if you are planning a family.
Making the Decision Together
This decision should not rest on one person or one appointment. The choice is best made jointly by you, your retina specialist, and your obstetrician, so that both your eye condition and your pregnancy are fully weighed1. Your retina specialist knows how urgent your eye problem is; your obstetrician knows your pregnancy. Bringing them together, rather than choosing alone, gives you the safest, best-informed plan.
At its heart, the decision balances two risks. On one side is your risk of permanent vision loss if a sight-threatening condition goes untreated; on the other is an uncertain, mostly theoretical risk to the pregnancy2. Neither risk is zero, and neither is fully known. That is uncomfortable, but it is the honest situation, and it is exactly why the answer is individual rather than one-size-fits-all.
Speak up early, before treatment is planned. Because a large share of exposed patients did not know they were pregnant at the time, many clinics now offer a pregnancy test before injections for people who could be pregnant1. If you are pregnant, might be, are trying, or are breastfeeding, say so at every visit. It is not an overreaction; it directly changes what your team recommends.
When to See a Doctor
Pregnancy and breastfeeding never change these red flags. See an eye doctor the same day, or go to an emergency room if none is available, for any of these:
- A sudden loss or sharp drop in vision
- A dark curtain, shadow, or missing area in your sight
- A sudden shower of new floaters or flashing lights
These can signal a serious retinal problem, and some cause permanent damage if not treated quickly, so being seen promptly protects your sight and does not commit you to any treatment.
Other changes are less urgent but still deserve a prompt call, ideally within a few days:
- Gradually blurring or distorted central vision
- Any change in a known eye condition, such as diabetic eye disease, during pregnancy
- Questions about whether and when to have a scheduled injection while pregnant or nursing
Diabetic eye disease in particular can change during pregnancy, so keep your planned eye checks even if your vision feels stable.
For the eye itself, a retina specialist manages these injections and conditions. For the pregnancy side, your obstetrician weighs in, and your pediatrician can advise on breastfeeding. For a sudden, severe vision change, an emergency room is a reasonable fallback if you cannot reach your eye doctor the same day.
Common Questions About Eye Injections in Pregnancy and Breastfeeding
The honest answer is that it is not proven either way, so it is treated as a shared decision. Experts generally advise avoiding these injections in pregnancy when reasonably possible, especially in the first trimester, and deciding each case with your eye and pregnancy teams2. The concern is theoretical, because the signal these drugs block also matters for the placenta. Sometimes waiting or an alternative is chosen; sometimes treating is safer for your sight. Your specific condition drives the answer.
There is no proven 'safe' drug or trimester, only relative caution. Guidance suggests avoiding the first trimester where possible, since that is when the baby's organs are forming, and any trimester decision still depends on how much vision is at risk2. Among the drugs, ranibizumab has the smallest amount reaching the bloodstream3, which some doctors weigh, but this has not been shown to change pregnancy outcomes. Your team chooses based on your situation.
Often, yes, depending on your condition. Alternatives can include laser treatment for diabetic disease, a steroid option for some swelling, or careful observation, since some pregnancy-related swelling improves after delivery2. These are not right for every problem, and some conditions genuinely need anti-VEGF to protect sight. The point of asking is to find out whether a safer-feeling option fits your particular diagnosis, which only your retina specialist can judge.
Most breastfeeding references say yes, though guidance is not unanimous. These large protein drugs pass into milk in tiny amounts and are mostly broken down in a baby's stomach, so milk databases generally consider breastfeeding compatible and often prefer ranibizumab6. However, some drug labels are more cautious, and one, aflibercept, says breastfeeding is not recommended during treatment8. Because sources differ, confirm the plan for your specific drug with your eye doctor and pediatrician.
No, its eye use is off-label, and that is worth understanding. Avastin is FDA-approved as a cancer treatment given through a vein, not for injection into the eye, so its common use as an eye injection is off-label7. Off-label does not mean unsafe or improper; it is widely used in the eye and supported by studies and long experience. It simply means the FDA has not formally reviewed it for eye use, which your doctor can explain in your case.
Possibly, depending on the drug. Some of these drugs' labels advise using effective contraception before, during, and for a few months after the last injection, because of the theoretical risk to a pregnancy8. The exact interval differs by drug, so ask which applies to yours. This is precautionary guidance based on how the drugs work, not evidence that a pregnancy has been harmed, and it matters most if you are planning to conceive.
More Questions, and Where These Answers Come From
Try not to panic, and tell your care team. Many exposed pregnancies in the largest review went on to a live birth, and a single early exposure has not been shown to cause harm, though the evidence is limited1. Let your eye doctor and obstetrician know so they can plan future care and monitoring together. An exposure that already happened cannot be undone, but it is not a reason to assume the worst, and your team can guide you from here.
It can, which is the other half of the balance. When a condition is actively threatening sight, delaying treatment can allow permanent, irreversible damage, so waiting is not automatically the safe choice1. This is exactly why the decision is individual: for a mild or stable problem, waiting may carry little risk, but for an aggressive one, the vision cost of waiting may outweigh the uncertain pregnancy risk. Your retina specialist can tell you which situation you are in.
You do, with expert guidance from both sides of the question. The decision is made jointly by you, your retina specialist, and your obstetrician, weighing your risk of vision loss against the uncertain risk to the pregnancy2. Your role is central: you weigh how much the treatment and the risks matter to you. Their role is to give you the clearest possible picture of both so your choice is fully informed.
These questions help you and your team make the decision well:
- How urgently does my eye condition need treatment, and what happens if we wait?
- Are there alternatives to an anti-VEGF injection that would fit my diagnosis?
- If we treat, which drug and timing would you choose in pregnancy, and why?
- Can my retina specialist and obstetrician talk directly about my case?
- If I am breastfeeding, is there anything I should do around an injection?
- Ong AY, et al. Intravitreal anti-VEGF injections in pregnancy and breastfeeding: a case series and systematic review. Eye (London) (2023). Pregnancy outcomes, unrecognized pregnancy, and the do-not-delay message.
- UK Teratology Information Service (UKTIS). Use of Ocular Antineovascularisation Agents in Pregnancy (2024). Avoid-if-possible guidance, first-trimester caution, alternatives, and shared decision-making.
- Avery RL, et al. Systemic pharmacokinetics after intravitreal ranibizumab, bevacizumab, or aflibercept. British Journal of Ophthalmology (2014). Systemic exposure differs by drug; ranibizumab lowest.
- Sakai T, et al. Potential safety signal of pregnancy loss with VEGF-inhibitor intraocular injection: a FAERS disproportionality analysis. Frontiers in Pharmacology (2022). Hypothesis-generating signal only.
- Bevacizumab. Drugs and Lactation Database (LactMed), NCBI Bookshelf. Very low or undetectable milk levels after intravitreal injection.
- Ranibizumab. Drugs and Lactation Database (LactMed), NCBI Bookshelf. Breastfeeding generally compatible; ranibizumab often preferred.
- Singh S, et al. Off-label use of intravitreal bevacizumab: a global conundrum. Indian Journal of Ophthalmology (2024). Bevacizumab eye use is off-label; the anti-VEGF agents.
- EYLEA (aflibercept) Prescribing Information. FDA label via DailyMed. Pregnancy risk-summary language, breastfeeding not recommended during treatment, and contraception advice.
- LUCENTIS (ranibizumab) Prescribing Information. FDA label via DailyMed. Pregnancy and lactation labeling for an FDA-approved anti-VEGF agent.